<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01284725</url>
  </required_header>
  <id_info>
    <org_study_id>2010-022859-30</org_study_id>
    <secondary_id>2010-15</secondary_id>
    <nct_id>NCT01284725</nct_id>
  </id_info>
  <brief_title>Weaning of Immunosuppression in Nephritis of Lupus</brief_title>
  <acronym>WIN-Lupus</acronym>
  <official_title>Weaning of Immunosuppression in Nephritis of Lupus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators wish to evaluate the discontinuation of maintenance immunosuppressive&#xD;
      treatment after 2 years in patients with stable remission after a proliferative lupus&#xD;
      nephritis. The patients will be continuing their treatment with hydroxychloroquine, possibly&#xD;
      associated with low dose corticosteroids.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      open multicenter randomized non-inferiority study, comparing 2 types of therapeutic&#xD;
      strategies after 2 years of maintenance treatment:&#xD;
&#xD;
        -  Group I: Continuation of immunosuppressive therapy with MMF or AZA, with a background&#xD;
           therapy with hydroxychloroquine, and possibly low-dose corticosteroids.&#xD;
&#xD;
        -  Group II: immunosuppressive treatment discontinuation, continuation of&#xD;
           hydroxychloroquine, and possibly low-dose corticosteroids (15 mg / day).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 2011</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Actual">January 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>discontinuation of maintenance immunosuppressive therapy</measure>
    <time_frame>2 years</time_frame>
    <description>to demonstrate that discontinuation of maintenance immunosuppressive therapy does not expose patients to a greater risk of relapse of proliferative lupus nephritis compared to the continuation of this treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>compare 2 therapeutic strategies</measure>
    <time_frame>2 years</time_frame>
    <description>to compare 2 therapeutic strategies in terms of relapse-free survival, overall survival , cumulative rate of 'relapse and / or death ', rates of adverse events , evolution of renal function , activity of SLE , consumption of steroids, impact on quality of life and economic impact.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Nephritis of Lupus</condition>
  <arm_group>
    <arm_group_label>immunosuppressive treatment discontinuation,</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Continuation of immunosuppressive therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>with MMF or AZA, with a background therapy with hydroxychloroquine, and possibly low-dose corticosteroids</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mycophenolate mofetil or azathioprine</intervention_name>
    <arm_group_label>Continuation of immunosuppressive therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunosuppressive treatment discontinuation</intervention_name>
    <arm_group_label>immunosuppressive treatment discontinuation,</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  At least 18-years-old patient, woman or man,&#xD;
&#xD;
          -  Patient having a lupus according to the criteria of the ACR,&#xD;
&#xD;
          -  Patient having presented a glomérulonéphrite lupique proliférative (class III or IV&#xD;
             Has +/-C, +/-list(classify) V) - first push or relapse - proved by renal biopsy,&#xD;
&#xD;
          -  Patient having received for this push a treatment of attack by steroids with strong&#xD;
             doses and cyclophosphamide or mycophénolate mofétil,&#xD;
&#xD;
          -  Patient in the course of treatment of interview(maintenance) by azathioprine or&#xD;
             mycophénolate mofétil for at least 2 years, and at most for 3 years, with at the time&#xD;
             of the inclusion, mycophénolate mofétil? 1 gram / day or azathioprine? 50 in the&#xD;
             daytime,&#xD;
&#xD;
          -  Patient in reply renal complete or partial (criteria of the European, secondary&#xD;
             consensus 2) since? 12 months,&#xD;
&#xD;
          -  Patient under Plaquenil ® since? 6 months with a hydroxychloroquinémie = 750 µg / L,&#xD;
&#xD;
          -  Patient having accepted of participated in the study and having signed a&#xD;
             lit(enlightened) consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient presenting a severe chronic renal insufficiency (DFG estimated(esteemed) by&#xD;
             MDRD &lt; 30 ml / min / 1.73m ²),&#xD;
&#xD;
          -  Patient having presented an extra-renal push having required an increase of corticoids&#xD;
             à&gt; 20 in the daytime during at least 7 days less than 6 months ago,&#xD;
&#xD;
          -  Patient presenting a contraindication to the hydroxychloroquine,&#xD;
&#xD;
          -  Unaffiliated patient in a national social security,&#xD;
&#xD;
          -  Minor patient.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>BERNARD BELAIGUES</last_name>
    <role>Study Director</role>
    <affiliation>Assistance Publique hôpitaux de Marseille</affiliation>
  </overall_official>
  <overall_official>
    <last_name>NOEMIE JOURDE CHICHE</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance publique Hôpitaux de marseille</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Assistance Publique Hopitaux de Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13354</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 21, 2011</study_first_submitted>
  <study_first_submitted_qc>January 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2011</study_first_posted>
  <last_update_submitted>February 25, 2021</last_update_submitted>
  <last_update_submitted_qc>February 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nephritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Azathioprine</mesh_term>
    <mesh_term>Immunosuppressive Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

